The challenges of antibiotic resistance in the development of new therapeutics.
Manuela, Oliveira.
The challenges of antibiotic resistance in the development of new therapeutics. - Sharjah : Bentham Science Publishers, (c)2015. - 1 online resource (279 pages) - Frontiers in Antimicrobial Agents ; v. 1 .
2.10.2. Propionibacterium Acnes.
FOREWORD ; PREFACE ; List of Contributors ; Introduction ; INTRODUCTION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Bacteriophages as Antibacterial Agents: Why are We Facing an Antibiotic Crisis and How Could Bacteriophages be of Help? ; 1. INTRODUCTION; 2. WHY ARE WE FACING AN ANTIBIOTIC (AB) CRISIS? ; 3. HOW TO RESOLVE THIS ANTIBIOTIC CRISIS? ; 4. BACTERIOPHAGES OR IN SHORT 'PHAGES'; 5. BACTERIOPHAGE THERAPY OR PHAGE THERAPY; 6. EXPERIMENTAL PHAGE THERAPY; 7. SAFETY ISSUES; 8. IN FACT WE LIVE IN AN "OCEAN" OF BACTERIOPHAGES; 9. SAFETY REQUIREMENTS FOR PHAGE THERAPY. 10. THE POTENTIAL ADVANTAGES OF PHAGE THERAPY VERSUS ANTIBIOTICS11. PHAGE THERAPY IN PUBLIC HEALTH; 12. WHY PHAGE THERAPY IS NOT YET IMPLEMENTED?; CONCLUSIONS AND PERSPECTIVES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Antimicrobial Peptides ; INTRODUCTION; 1. WHAT ARE ANTIMICROBIAL PEPTIDES (AMPS); 1.1. Mode of Action; 1.2. Immune System; 1.3. Resistance; 2. CHRONOLOGY OF AMPS DISCOVERY -- A BRIEF HISTORY; 2.1. Classification of AMPs; 2.1.1. Biological Source; 2.1.2. Biological Functions; 2.1.3. Biosynthesis; 2.1.4. Molecular Properties; 2.1.5. Molecular Targets. 2.1.6. Three-Dimensional (3D) Structure2.2. Currently Active AMPs Databases; 3. THERAPEUTIC APPLICATIONS OF AMPS; 3.1. Anticancer AMPs; 3.2. Antiviral AMPs; 3.3. Anti-parasitic AMPs; 3.4. New Generation of AMPs; CONCLUDING REMARKS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Probiotics: Ways of Action and Beneficial Effects ; 1. INTRODUCTION; 2. SELECTION OF PROBIOTICS; 3. COMMERCIALLY IMPORTANT PROBIOTICS; 4. MECHANISMS OF ACTION OF PROBIOTICS; 4.1. Immunomodulation; 4.2. Direct Effects on Other Microorganisms; 5. BENEFICIAL HEALTH EFFECTS OF PROBIOTICS. 5.1. Alleviation of Lactose Intolerance5.2. Effect on Helicobacter Pylori Eradication ; 5.3. Anti-carcinogenic Effect; 5.4. Cholesterol-lowering Effects; 5.5. Allergy and Atopic Dermatitis; 5.6. Inflammatory Diseases and Bowel Syndromes ; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Immunotherapy ; 1. BACTERIAL INFECTIVITY, IMMUNE RESPONSE AND MULTIRESISTANT INFECTIONS : NEW PERSPECTIVES; 1.1. Introduction; 1.2. Host Resistance; 1.3. Bacterial Strategies for Evading, Surviving Host Defense Systems and Create Infection; 2. IMMUNOTHERAPY; 2.1. Introduction.
9781681081403
Drug resistance in microorganisms.
Electronic Books.
QR177 / .C435 2015
The challenges of antibiotic resistance in the development of new therapeutics. - Sharjah : Bentham Science Publishers, (c)2015. - 1 online resource (279 pages) - Frontiers in Antimicrobial Agents ; v. 1 .
2.10.2. Propionibacterium Acnes.
FOREWORD ; PREFACE ; List of Contributors ; Introduction ; INTRODUCTION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Bacteriophages as Antibacterial Agents: Why are We Facing an Antibiotic Crisis and How Could Bacteriophages be of Help? ; 1. INTRODUCTION; 2. WHY ARE WE FACING AN ANTIBIOTIC (AB) CRISIS? ; 3. HOW TO RESOLVE THIS ANTIBIOTIC CRISIS? ; 4. BACTERIOPHAGES OR IN SHORT 'PHAGES'; 5. BACTERIOPHAGE THERAPY OR PHAGE THERAPY; 6. EXPERIMENTAL PHAGE THERAPY; 7. SAFETY ISSUES; 8. IN FACT WE LIVE IN AN "OCEAN" OF BACTERIOPHAGES; 9. SAFETY REQUIREMENTS FOR PHAGE THERAPY. 10. THE POTENTIAL ADVANTAGES OF PHAGE THERAPY VERSUS ANTIBIOTICS11. PHAGE THERAPY IN PUBLIC HEALTH; 12. WHY PHAGE THERAPY IS NOT YET IMPLEMENTED?; CONCLUSIONS AND PERSPECTIVES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Antimicrobial Peptides ; INTRODUCTION; 1. WHAT ARE ANTIMICROBIAL PEPTIDES (AMPS); 1.1. Mode of Action; 1.2. Immune System; 1.3. Resistance; 2. CHRONOLOGY OF AMPS DISCOVERY -- A BRIEF HISTORY; 2.1. Classification of AMPs; 2.1.1. Biological Source; 2.1.2. Biological Functions; 2.1.3. Biosynthesis; 2.1.4. Molecular Properties; 2.1.5. Molecular Targets. 2.1.6. Three-Dimensional (3D) Structure2.2. Currently Active AMPs Databases; 3. THERAPEUTIC APPLICATIONS OF AMPS; 3.1. Anticancer AMPs; 3.2. Antiviral AMPs; 3.3. Anti-parasitic AMPs; 3.4. New Generation of AMPs; CONCLUDING REMARKS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Probiotics: Ways of Action and Beneficial Effects ; 1. INTRODUCTION; 2. SELECTION OF PROBIOTICS; 3. COMMERCIALLY IMPORTANT PROBIOTICS; 4. MECHANISMS OF ACTION OF PROBIOTICS; 4.1. Immunomodulation; 4.2. Direct Effects on Other Microorganisms; 5. BENEFICIAL HEALTH EFFECTS OF PROBIOTICS. 5.1. Alleviation of Lactose Intolerance5.2. Effect on Helicobacter Pylori Eradication ; 5.3. Anti-carcinogenic Effect; 5.4. Cholesterol-lowering Effects; 5.5. Allergy and Atopic Dermatitis; 5.6. Inflammatory Diseases and Bowel Syndromes ; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Immunotherapy ; 1. BACTERIAL INFECTIVITY, IMMUNE RESPONSE AND MULTIRESISTANT INFECTIONS : NEW PERSPECTIVES; 1.1. Introduction; 1.2. Host Resistance; 1.3. Bacterial Strategies for Evading, Surviving Host Defense Systems and Create Infection; 2. IMMUNOTHERAPY; 2.1. Introduction.
9781681081403
Drug resistance in microorganisms.
Electronic Books.
QR177 / .C435 2015